References
- Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338(13): 853–60
- Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321(24):1621–5
- Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373(6510): 123–6
- US Department of Health and Human Services, Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.hivatis.org. Accessed Feb 15, 2000
- Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med 2000; 132:306–11
- Baxter JD, Mayers DL, Wentworth DN, et al. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic resistance testing (GART) in patients failing antiretroviral therapy. (Abstr LB8) Proceedings, 6th Conference on Retroviruses and Opportunistic Infections. Chicago: 1999 Jan 31-Feb 4. Available at: http://www.retroconference.org/99. Accessed Jan 24, 2000
- Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353(9171): 2195–9
- Maulin L, Gerare Y, de la Tribonniere X, et al. Emerging complication of antiretroviral therapy: symptomatic hyperlactatemia. (Abstr 1285) Proceedings, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 Sept 26–9. Available at: http://www.medscape.com. Accessed Jan 24, 2000
- Boxwell DE, Styrt BA. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptase inhibitors (NRTIs). (Abstr 1284) Proceedings, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 Sept 26–9. Available at: http://www.medscape.com. Accessed Jan 24, 2000
- Schiano TD, Lissoos TW, Ahmed A, et al. Lamivudine- stavudine-induced liver failure in hepatitis B cirrhosis. Am J Gastroenterol 1997; 92(9): 1563–4
- Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long- term nucleoside analogue therapy. AIDS 1999; 13 (13): 1659–67
- Dusek A, Hall D, Lamson M, et al. Once-daily dosing of nevirapine: a retrospective, cross-study analysis. (Abstr 12360) Proceedings, 12th World AIDS Conference. Geneva: 1998 Jun 28-Jul 3. Available at: http://www.abstracts-on-line.com. Accessed Jan 24, 2000
- Eron J, McKinley G, Lecrerq P, et al. Potent antiviral activity using delavirdine and reduced-dose indinavir combination therapies: a 48-week analysis. (Abstr 535) Proceedings, 7th Conference on Retroviruses and Opportunistic Infections. San Francisco: 2000 Jan 30-Feb 2. Available at: http://www.retroconference.org. Accessed Feb 15, 2000
- Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipid-aemia, and insulin resistance. Lancet 1998; 351(9119): 1881–3
- O'Brien LW. Interactions and toxicities of drugs for HIV disease. AIDS Reader 1998; 8:28–36
- Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36(4):289–304
- Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63(4):453–64